Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Free Report

White Paper_2017_State of China Life Science

State of China Life Science - 2017H1

Over $10B invested in last 18 months! Download free report on life science investment in China.

Sinovac Announces Much Lower First Quarter

publication date: May 15, 2009
View a Printer Friendly version of this page, allowing you to print the page.

Sinovac Biotech (北京科兴生物制品有限公司) reported a substantial 26% decline in Q1 sales, which fell from $8.9 million in 2008 to only $6.6 million this year. The revenue drop left net income at a barely positive level of just $25,000, down from $1.6 million in last year’s first quarter. Nevertheless, despite the weakening in its revenue trend, Sinovac courageously called for full-year 2009 revenues of $55-$60 million, a 20% increase. It’s a long way from a $6.6 million first quarter to a $60 million year. More details...

Stock Symbol: (NYSE Amex: SVA)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China